A Pentaherbs Capsule as a Treatment Option for Atopic Dermatitis in Children: An Open-Labeled Case Series

2004 ◽  
Vol 32 (06) ◽  
pp. 941-950 ◽  
Author(s):  
Kam-Lun Ellis Hon ◽  
Ting-Fan Leung ◽  
Yin Wong ◽  
Wai-Kei Christopher Lam ◽  
De-Qi Bill Guan ◽  
...  

Traditional Chinese Medicine (TCM) has been used in patients with atopic dermatitis (AD), but its therapeutic effects are debatable. We evaluated the clinical and biochemical effects of a TCM capsule (PentaHerbs capsule) in children with AD. After a run-in period of 4 weeks, children old enough to manage oral medication were admitted and their disease severity was evaluated by the SCORing Atopic Dermatitis (SCORAD) index. Blood was obtained for complete blood count, total and allergen-specific immunoglobulin E (IgE), biochemical studies and inflammatory markers of AD severity [serum cutaneous T cell-attracting chemokine (CTACK), macrophage-derived chemokine (MDC), thymus and activation-regulated chemokine (TARC) and eosinophil cationic protein (ECP)] prior to, and after 3 months of, TCM use. Three PentaHerbs capsules twice a day were prescribed for 4 months. Patients were followed monthly to ensure compliance, and SCORAD scores were obtained at each visit. Five boys and four girls participated in the study. All patients had detectable food or inhalant-specific IgE in serum. There was significant improvement in the overall and component SCORAD scores. There were no significant differences between the pre- and post-treatment values of the serum CTACK, MDC, TARC and ECP levels but CTACK showed a decreasing trend (p=0.069). No clinical or biochemical evidence of any adverse drug reaction was observed during the study period. The PentaHerbs capsules were well tolerated by the children and apparent beneficial effects were noted clinically. A larger, randomized placebo-controlled study is required to confirm the efficacy of this formulation for AD.

Author(s):  
Gavin P Spickett

Introduction Allergen-specific IgE Allergen-specific IgG antibodies Basophil activation test CD23, soluble (Fcε‎ receptor) C3a, C4a, and C5a (anaphylotoxins) Challenge tests Drug allergy testing Eosinophil cationic protein (ECP) Eosinophil count Flow-CAST® and CAST-ELISA® Histamine-release assays Immunoglobulin E (total IgE) IgE autoantibodies/IgE receptor antibodies...


1994 ◽  
Vol 36 (2) ◽  
pp. 146-149 ◽  
Author(s):  
ATSUO URISU ◽  
YASUTO KONDO ◽  
EIKO WADA ◽  
FUMIYA HORIBA ◽  
MITSUTOSI TSURUTA ◽  
...  

2020 ◽  
Vol 41 (1) ◽  
pp. 59-65
Author(s):  
Jung Hye Byeon ◽  
Wonsuck Yoon ◽  
So Hyun Ahn ◽  
Hyo Sun Lee ◽  
Seunghyun Kim ◽  
...  

Background: Atopic dermatitis (AD) is chronic pruritic inflammatory skin disease in children. Interleukin (IL) 31 is a recently discovered cytokine associated with chronic skin inflammation and pruritus. Objectives: The aims of this study were to determine whether serum IL-31 levels are increased in children with AD and to examine the relationship between IL-31 and other clinical biomarkers in AD. Methods: Serum cytokine levels, including IL-31, IL-4, and IL-12, were measured in 38 patients with AD and 10 healthy children. Peripheral blood eosinophils, serum immunoglobulin E levels, eosinophil cationic protein, and thymic stromal lymphopoietin (TSLP) were measured. We also estimated the clinical severity of AD by using the Scoring Atopic Dermatitis (SCORAD) index by a single clinician. Results: The serum IL-31 levels were significantly higher in the patients with AD than in the healthy children. IL-31 correlated well with the SCORAD index and blood eosinophilic inflammatory markers. The serum level of TSLP was also higher in patients with AD than in the healthy children; however, levels of IL-4 and IL-12 were not different between AD and healthy children. There was no significant difference in serum IL-31 levels between patients with atopic AD and nonatopic AD. Conclusion: This study showed that serum IL-31 levels were significantly elevated in patients with AD than in the healthy children and correlated well with disease severity. IL-31 seemed to be one of the cytokines that induce pruritus and eosinophilic inflammation in AD. Serum IL-31 correlated with pruritic symptoms and disease course of AD.


Author(s):  
Kouichi Ikai ◽  
Atsuhiko Ogino ◽  
Ikuko Furukawa ◽  
Motoaki Ozaki ◽  
Mayumi Fujita ◽  
...  

1991 ◽  
Vol 96 (2) ◽  
pp. 175-178 ◽  
Author(s):  
R. Paganelli ◽  
E. Fanales-Belasio ◽  
D. Carmini ◽  
E. Scala ◽  
P. Meglio ◽  
...  

2006 ◽  
Vol 45 (10) ◽  
pp. 1156-1160 ◽  
Author(s):  
Murat-Sušić Slobodna ◽  
Lipozenčić Jasna ◽  
Žiǎić Vesna ◽  
Husar Karmela ◽  
Marinović Branka

Parasite ◽  
2020 ◽  
Vol 27 ◽  
pp. 32 ◽  
Author(s):  
Jean-François Magnaval ◽  
Judith Fillaux ◽  
Sophie Cassaing ◽  
Alexis Valentin ◽  
Xavier Iriart ◽  
...  

To assess the possible influence of atopy on the clinical picture of human toxocariasis, a retrospective study was carried out using file records for patients who attended the Outpatient Clinic of Parasitology in Toulouse University Hospitals. A total of 106 file records for patients who had been diagnosed with common/covert toxocariasis were extracted from the database. Forty-nine patients (20 females and 29 males) were considered atopic since they exhibited a long (≥ 1 year) history of various allergic issues along with a titer ≥ 0.7 kIU/L for specific IgE against at least two out of nine mixes of common inhalant allergens. Fifty-seven patients (42 females and 15 males) were designated nonatopic on the basis of a negative result (<0.35 kIU/L) of the test for specific IgE. Demographic (age and sex), clinical (20 signs or symptoms) and laboratory (blood eosinophil count, eosinophil cationic protein, serum total IgE, and specific anti-Toxocara IgE) variables were investigated by bivariate analysis followed by multivariate regression analysis using “atopy” as the outcome variable. On the basis of our results, the clinical or laboratory picture of toxocaral disease was not affected by the presence of an atopic status.


2019 ◽  
Vol 2019 ◽  
pp. 1-13
Author(s):  
Fenggen Yan ◽  
Jing Zhang ◽  
Xiong Li ◽  
Xiumei Mo ◽  
Junfeng Liu ◽  
...  

Atopic dermatitis (AD), also known as atopic eczema, is a chronic pruritic inflammatory skin disease. The available systemic therapies for atopic dermatitis are inadequate. Objective. This study aimed to evaluate the effects of the Chinese herbal formula Pei Tu Qing Xin (PTQX) on dermatitis severity and ear swelling, immunomodulation, and the infiltration of mast cells in a mouse model of 1-chloro-2,4-dinitrobenzene- (DNCB-) induced AD. Methods. AD-like symptoms were induced by DNCB in NC/Nga mice. Skin lesions, dermatitis, ear swelling, and scratching behaviour were evaluated. Changes in the T-helper type 1 (Th1), Th2, Th17, and regulatory T (Treg) subtypes and immunoregulation in the spleen and lymph nodes were detected by flow cytometry. Results. Histopathological and immunohistochemical analyses demonstrated that PTQX decreased the DNCB-mediated induction of mast cells and infiltration of inflammatory cells in the ear and dorsal skin. PTQX also reduced the DNCB-induced increase in the serum immunoglobulin E level, pruritus, and dermatitis (red, flaky areas) on the dorsal skin. Furthermore, PTQX regulated the balance between the populations of Th1, Th2, Th17, and Treg cells (particularly the latter two) in the lymph nodes. Conclusions. Our results suggest that the Chinese herbal formula PTQX can alleviate symptoms of AD, such as epithelial damage, redness, swelling, and pruritus, and potentially be used to treat this condition.


Sign in / Sign up

Export Citation Format

Share Document